Evidence map›Paper›PMID 32565951›Full record

ArticleOncology letters2020

STAT1 is a modulator of the expression of frequently rearranged in advanced T-cell lymphomas 1 expression in U251 cells.

Geng Guo, Shule Wang, Yining Hao, Yeqing Ren, Yongqiang Wu, Jianping Zhang, Dong Liu

Open access · diamondAbstract read
In one paragraph

Article in Oncology letters, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 54% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Geng GuoDepartment of Neurosurgery, The First Hospital, Shanxi Medical University, Taiyuan, Shanxi 030000, P.R. China.
Shule WangDepartment of Neurosurgery, The First Hospital, Shanxi Medical University, Taiyuan, Shanxi 030000, P.R. China.
Yining HaoDepartment of Neurosurgery, The First Hospital, Shanxi Medical University, Taiyuan, Shanxi 030000, P.R. China.
Yeqing RenDepartment of Neurosurgery, The First Hospital, Shanxi Medical University, Taiyuan, Shanxi 030000, P.R. China.
Yongqiang WuDepartment of Neurosurgery, The First Hospital, Shanxi Medical University, Taiyuan, Shanxi 030000, P.R. China.
Jianping ZhangDepartment of Neurosurgery, The First Hospital, Shanxi Medical University, Taiyuan, Shanxi 030000, P.R. China.
Dong LiuDepartment of Neurosurgery, The First Hospital, Shanxi Medical University, Taiyuan, Shanxi 030000, P.R. China.
Shanxi Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aberrant expression of frequently rearranged in advanced T-cell lymphomas 1 (FRAT1) contributes to poor prognosis in a number of carcinomas. However, its role in glioma remains controversial. In the present study, gene expression profiling was performed using Kyoto Encyclopedia of Genes and Genomes (KEGG), Gene Ontology (GO) functional enrichment and ingenuity pathway analysis (IPA) to evaluate the differential expression of genes and proteins in FRAT1 knockdown U251 glioma cells in comparison with the control. Western blot analysis was conducted to assess the expression levels of FRAT1 and STAT1. A total of 895 downregulated genes were identified in FRAT1-silenced U251 cells. The most enriched processes determined by GO and KEGG analysis of the 895 differentially expressed genes were associated with proliferation, migration and invasion. According to IPA, significant canonical pathways, including the interferon, hepatic fibrosis and Wnt/β-catenin signaling pathways, were identified to be the major enriched pathways. The elevated expression of STAT1 in U251 cells was validated. These results highlighted the regulatory role of FRAT1 in glioma cells with upregulated STAT1 expression.

Indexed as

frequently rearranged in advanced T cell lymphomas 1pathwaysignal transducer and activator of transcription 1U251 cells

Identifiers

PMID32565951
PMCPMC7285825
OpenAlexW3017978794

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.